Literature DB >> 10816596

Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis.

L Lundin1, H Larsson, J Kreuger, S Kanda, U Lindahl, M Salmivirta, L Claesson-Welsh.   

Abstract

Fibroblast growth factors (FGFs) are known to induce formation of new blood vessels, angiogenesis. We show that FGF-induced angiogenesis can be modulated using selectively desulfated heparin. Chinese hamster ovary cells (CHO677) deficient in heparan sulfate biosynthesis were employed to assess the function of heparin/heparan sulfate in FGF receptor-1 (FGFR-1) signal transduction and biological responses. In the presence of FGF-2, FGFR-1 kinase and subsequent mitogen-activated protein kinase Erk2 activities were augmented in a dose-dependent manner, whereas high concentrations of heparin resulted in decreased activity. The length of the heparin oligomer, minimally an 8/10-mer, was critical for the ability to enhance FGFR-1 kinase activity. The N- and 2-O-sulfate groups of heparin were essential for binding to FGF-2, whereas stimulation of FGFR-1 and Erk2 kinases by FGF-2 also required the presence of 6-O-sulfate groups. Sulfation at 2-O- and 6-O-positions was moreover a prerequisite for binding of heparin to a lysine-rich peptide corresponding to amino acids 160-177 in the extracellular domain of FGFR-1. Selectively 6-O-desulfated heparin, which binds to FGF-2 but fails to bind the receptor, decreased FGF-2-induced proliferation of CHO677 cells, presumably by displacing intact heparin. Furthermore, FGF-2-induced angiogenesis in chick embryos was inhibited by 6-O-desulfated heparin. Thus, formation of a ternary complex of FGF-2, heparin, and FGFR-1 appears critical for the activation of FGFR-1 kinase and downstream signal transduction. Preventing complex formation by modified heparin preparations may allow regulation of FGF-2 functions, such as induction of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816596     DOI: 10.1074/jbc.M908930199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications.

Authors:  Neetu M Gulati; Phoebe L Stewart; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2018-05-15       Impact factor: 4.939

2.  Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells.

Authors:  Gui Su; Kristy Meyer; Chilkunda D Nandini; Dianhua Qiao; Shahriar Salamat; Andreas Friedl
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  Novel glycosaminoglycan biosynthetic inhibitors affect tumor-associated angiogenesis.

Authors:  Karthik Raman; Masayuki Ninomiya; Thao Kim Nu Nguyen; Yasuhiro Tsuzuki; Mamoru Koketsu; Balagurunathan Kuberan
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

Review 4.  Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery.

Authors:  Tobias Miller; Melissa C Goude; Todd C McDevitt; Johnna S Temenoff
Journal:  Acta Biomater       Date:  2013-10-09       Impact factor: 8.947

5.  Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Biochem Biophys Res Commun       Date:  2010-06-17       Impact factor: 3.575

6.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

Review 7.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

Review 8.  Application of polysaccharides for surface modification of nanomedicines.

Authors:  Kyung-Oh Doh; Yoon Yeo
Journal:  Ther Deliv       Date:  2012-12

9.  Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Authors:  Erik H Knelson; Angela L Gaviglio; Jasmine C Nee; Mark D Starr; Andrew B Nixon; Stephen G Marcus; Gerard C Blobe
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

10.  Endosulfatases SULF1 and SULF2 limit Chlamydia muridarum infection.

Authors:  J H Kim; C Chan; C Elwell; M S Singer; T Dierks; H Lemjabbar-Alaoui; S D Rosen; J N Engel
Journal:  Cell Microbiol       Date:  2013-04-09       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.